As a leading innovator of research, discovery, and development in the pharmaceutical industry, C4X Discovery is on a quest to uncover and design new drugs that could have a huge impact on the healthcare world in the years to come. While the process of taking a new drug from concept to market typically moves along at a slow, methodical pace, the team at C4X has found Unreal Engine is the perfect catalyst for unlocking the path forward in faster, more immersive ways.
Grant awarded to investigate efficacy of C4X3256 in preclinical models of cocaine addiction, further demonstrating the efficacy of C4X3256 across broad addiction indications
24 July 2018 – C4X Discovery Holdings plc (AIM:C4XD), a pioneering drug discovery company, is pleased to announce that C4X Discovery’s C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an oral Orexin-1 receptor antagonist, has demonstrated an excellent safety profile and preclinical efficacy in models of nicotine addiction.
Eva-Lotta Allan appointed Non-Executive Chairman of the Board
Board further strengthened with the appointment of Natalie Walter
4 July 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Eva-Lotta Allan and Natalie Walter have been appointed as Non-Executive Chairman of the Board and Non-Executive Director respectively, with immediate effect.
Scientists in Manchester are working on a drug to kill cravings.
After spending his youth hooked on drugs and alcohol, comedian Russell Brand came to a conclusion: addiction is a disease. For him it began with overeating as a child, and by the time he reached young adulthood, Brand had moved on to crack cocaine and heroin. Today, despite being clean for 15 years, the entertainer is adamant that he is still an addict — and that it is a medical condition.
We are delighted to have won the Best Technology Award at the European Mediscience Awards. Thanks to the organisers for a great evening.
Blue skies, streaked with clouds – an unending expanse of grid to stand on – and one massive molecule: in the drug-discovering virtual world, for the first time, scientists can get up close and personal with the drugs they’re designing. Grabbing hold of a virtual molecule, floating in space before them, using two lightsaber-wielding claw-like hands, the chemist can get as close to touching the desired structure as is (meta)physically possible.
“Starting to use VR was quite transformative, because all of a sudden the molecules become part of my world and I can manipulate them in space just ahead of me, like you would do comparing two oranges and two apples,” says Thorsten Nowak, medicinal chemist at C4XD. With the VR platform, drug discovery “became as visual as it can really ever be”.
Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive's Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256.
It is the first major partnership for C4X, which will receive US$10mln up front and a further US$284mln dependent on how successful the drug proves.
1 May 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a joint research collaboration with e-Therapeutics plc (AIM: ETX) to identify novel mechanistic insights into Parkinson’s Disease (PD). The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3® novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will use the outputs from C4XD’s Taxonomy3® genetic analysis of PD and apply an NDD approach to identify novel intervention strategies which it is expected will lead to new approaches for the treatment of PD.